Search results: Sage Journals

Available accessResearch articleFirst published July, 2016

HR Positioning—A Matter of National Culture? Facts from Hungary

Katharina Thill, Barbara Covarrubias Venegas, József Poór

Business Perspectives and Research

Open accessResearch articleFirst published 2024

Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study

Qingyuan Zhang, Pin Zhang, Min Yan [...]

Therapeutic Advances in Medical Oncology

Retricted accessEditorialFirst published February, 1972

Position Statement on HR I

Ellen P. Manser

Families in Society: The Journal of Contemporary Social Services

Open accessResearch articleFirst published April, 2025

Exploring the HR analyst position around the globe

Rene Arseneault, Jialiang Yang

International Journal of Cross Cultural Management

Open accessResearch articleFirst published 2024

HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis

Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan [...]

Therapeutic Advances in Medical Oncology

Available accessResearch articleFirst published June, 2026

Predictive Value of Magee Equation 3 for Tumor and Axillary Response to Neoadjuvant Chemotherapy in HR-Positive,HER2-Negative Breast Cancer

Mustafa Onur Beştaş, Erkan Güler, Ahmet Dağ [...]

The American Surgeon™

Available accessResearch articleFirst published 2025

Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated,HR-positive,HER2-negative invasive breast cancer: A systematic review

Chris Larck, Joseph B Elmes, R. Wesley Haynes [...]

Journal of Oncology Pharmacy Practice

Open accessReview articleFirst published 2015

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive,Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Adam M. Brufsky

Clinical Medicine Insights: Oncology

Open accessResearch articleFirst published 2025

A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)

Bora Lim, Angela Marx, Megumi Kai [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2023

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+,HER2−,node-positive,high-risk early breast cancer

Shani Paluch-Shimon, Patrick Neven, Jens Huober [...]

Therapeutic Advances in Medical Oncology

Available accessResearch articleFirst published July, 2016

HR Positioning—A Matter of National Culture? Facts from Hungary

Katharina Thill, Barbara Covarrubias Venegas, József Poór

Business Perspectives and Research

Open accessResearch articleFirst published 2024

Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study

Qingyuan Zhang, Pin Zhang, Min Yan [...]

Therapeutic Advances in Medical Oncology

Retricted accessEditorialFirst published February, 1972

Position Statement on HR I

Ellen P. Manser

Families in Society: The Journal of Contemporary Social Services

Open accessResearch articleFirst published April, 2025

Exploring the HR analyst position around the globe

Rene Arseneault, Jialiang Yang

International Journal of Cross Cultural Management

Open accessResearch articleFirst published 2024

HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis

Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan [...]

Therapeutic Advances in Medical Oncology

Available accessResearch articleFirst published June, 2026

Predictive Value of Magee Equation 3 for Tumor and Axillary Response to Neoadjuvant Chemotherapy in HR-Positive,HER2-Negative Breast Cancer

Mustafa Onur Beştaş, Erkan Güler, Ahmet Dağ [...]

The American Surgeon™

Available accessResearch articleFirst published 2025

Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated,HR-positive,HER2-negative invasive breast cancer: A systematic review

Chris Larck, Joseph B Elmes, R. Wesley Haynes [...]

Journal of Oncology Pharmacy Practice

Open accessReview articleFirst published 2015

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive,Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Adam M. Brufsky

Clinical Medicine Insights: Oncology

Open accessResearch articleFirst published 2025

A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)

Bora Lim, Angela Marx, Megumi Kai [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2023

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+,HER2−,node-positive,high-risk early breast cancer

Shani Paluch-Shimon, Patrick Neven, Jens Huober [...]

Therapeutic Advances in Medical Oncology